(Sharecast News) - Johnson & Johnson raised its full-year outlook on Wednesday after second-quarter sales rose 6.6% to $25.31bn, ahead of market expectations, while adjusted earnings increased 4.7% to $2.90 per share.
Innovative Medicine sales grew 7.8% to $16.38bn, driven by strong demand for Tremfya, Darzalex, Carvykti and Caplyta, offsetting declines...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE